ライフサイエンスコーパス: syngeneic

1 was performed on female BALB/C mice bearing syngeneic 4T07 (nonmetastatic) and 4T1 (metastatic) TNBC

2 d prolonged overall survival in mice bearing syngeneic 4T07 and 4T1 tumors.

3 o(LA)(8)-PTX-PM (10%) and PTX-PM (10%) in a syngeneic 4T1-luc breast tumor model based on measuremen

4 received bilateral orthotopic injections of syngeneic 67NR, 4T07, or 4T1cells (1 x 10(5) cells per i

5 determined after intravenous inoculation of syngeneic 9801L pancreas carcinoma cells.

6 simulated by using bone graft material from syngeneic ACTB-eGFP-expressing mice.

7 One patient underwent a syngeneic allograft and 25 HDM/ASCT (16 of whom subseque

8 DHB had no effect on the growth of syngeneic allografts in wild-type mice but opposed the a

9 Six syngeneic and 25 allogeneic transplants were performed.

10 Syngeneic and allogeneic heterotopic penile transplantat

11 Syngeneic and allogeneic orthotopic hindlimb transplanta

12 B-cell reconstitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depl

13 t of an antibody-mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney transplant mo

14 s severely compromises antitumor immunity in syngeneic and genetic models of colorectal cancer (CRC),

15 expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lun

16 e and adaptive immune-dependent responses in syngeneic and humanized mouse models of telomerase-expre

17 er of GICs in vivo and prolonged survival in syngeneic and patient-derived orthotopic xenograft (PDOX

18 ces the survival of GBM-bearing mice in both syngeneic and T-cell receptor transgenic models.

19 All syngeneic and tacrolimus-treated grafts survived until e

20 ack and was observed after injection of both syngeneic and xenogeneic cells.

21 ore effective than either drug alone in both syngeneic and xenograft mouse models.

22 261 murine glioma cells are widely used as a syngeneic animal model of glioma, however, it has become

23 ce, C1q-deficient (C1qa(-/-)) mice bearing a syngeneic B16 melanoma exhibit a slower tumour growth an

24 ti-PD-L1, but not anti-CTLA4, therapy in the syngeneic B16F10 melanoma model.

25 d untreated, contralateral tumor growth in a syngeneic B16F10 mouse melanoma model.

26 fails to generate antitumor immunity against syngeneic B16F10 tumors in mice.

27 pic breast cancer model using 4T1luc-bearing syngeneic BALB/c mice.

28 reast cancer (BC) cells and RT-treated mouse syngeneic BC.

29 Our results demonstrate that syngeneic bile duct antigens efficiently break immune to

30 autoimmune cholangitis via immunization with syngeneic bile duct protein (BDP).

31 th equal potency to those administered after syngeneic BMT.

32 In a syngeneic breast cancer mouse model overexpressing GLUT1

33 smaller and fewer tumors and metastases than syngeneic C57/Bl6 wild-type mice.

34 Syngeneic C57BL/6 donor islets were transplanted into th

35 cells and 20 million splenocytes from either syngeneic C57BL/6 or allogeneic BALB/c donors.

36 mice (Tgfbr2(fl/fl) ) and transplanted into syngeneic C57BL/6J mice by splenic injection.

37 ies of the promising cationic amphiphiles in syngeneic C57BL/6J mice under prophylactic settings.

38 injected B16rho(0) mouse melanoma cells into syngeneic C57BL/6N(su9-DsRed2) mice that express red flu

39 Using syngeneic cancer cells (EO771 mammary carcinoma and B16-

40 tively treated established tumors in diverse syngeneic cancer models, and the systemic effect was dep

41 We demonstrated that both allogeneic and syngeneic CAR T cells show initial expansion as effector

42 1R signaling pathways during IRI, we treated syngeneic cardiac transplant recipients at 1-hour posttr

43 Using syngeneic cardiac transplantation to model ischemia-repe

44 y of diabetes reversal of allogeneic but not syngeneic CC islets was lower than that of naked islets,

45 rived mouse tumoroids and KPC-derived murine syngeneic cell line growth compared to gemcitabine/afati

46 We have isolated two syngeneic cell lines (indolent and aggressive) through i

47 ntation of green fluorescent protein-labeled syngeneic colorectal cancer cells.

48 In a syngeneic colorectal cancer model, the inhibitor increas

49 In a syngeneic colorectal cancer mouse model, combined admini

50 a diminished 5-FU therapeutic response in a syngeneic colorectal tumor model consistent with increas

51 the bacterial population dynamics in ectopic syngeneic colorectal tumours in mice via a luminescent r

52 rations compared with naive (P < 0.0001) and syngeneic controls (P = 0.0023).

53 Compared with syngeneic controls, RIC mice with GVHD showed evidence o

54 n grades in allogeneic animals compared with syngeneic controls.

55 d from draining lymph nodes of allogeneic or syngeneic corneal transplanted BALB/c mice.

56 ed inflammation when they were recipients of syngeneic corneal transplants but also exhibited signifi

57 d intracoronarily vehicle or 1 million male, syngeneic CPCs.

58 Using syngeneic CRC xenografts, we observed significantly high

59 ltivalent M2pep and M2pepKLA analogs using a syngeneic CT-26 tumor cell suspension.

60 s, this original demonstration used congenic/syngeneic dam and foster pup pairs.

61 In a syngeneic DLBCL mouse model, this PARP1-targeted PET ima

62 specific STAT3-knockdown postnatal mice-plus syngeneic fibroblast cell-transplant models-we demonstra

63 r collagen-dense (Col1a1(tm1Jae/+), mCol1a1) syngeneic FVB/N female mice.

64 Syngeneic GBM models were established in mice perinatall

65 sCD and tested in animal models of human and syngeneic GBM.

66 Similar growth inhibition was observed in syngeneic GL261 GBM (p < 0.05).

67 We treated mice bearing orthotopic syngeneic (Gl261) GBMs or human (MGG8) GBM xenografts wi

68 B signaling (p65) in myeloid cells inhibited syngeneic glioblastoma (GBM) through decreased CD45 infi

69 Furthermore, using a syngeneic glioma model, w-MWNT-ANG showed enhanced uptak

70 l survival of tumor-bearing mice in the GL26 syngeneic glioma model.

71 dramatically extended survival of mice in 2 syngeneic glioma models, GL261 and CT2A.

72 Finally, in mice harboring syngeneic gliomas, an inhibitor of 2HG synthesis complem

73 geneic grafts without cold ischemia time and syngeneic grafts did not develop any TV.

74 ESC-GEMM chimera experiments in vitro and in syngeneic grafts in vivo Thus, when combined with sophis

75 We used an immunocompetent syngeneic HCC mouse model for the study.

76 Syngeneic hepatocytes engrafted in liver, whereas alloge

77 We crossed DO mice with syngeneic HER2 transgenic mice to study the genetics of

78 In 2 syngeneic HER2+ self-antigen tumor models, we found that

79 In a syngeneic HLA-A2-transgenic mouse model of large establi

80 This syngeneic HNSCC mouse model provides a platform to accel

81 cell responses and reduced tumour growth in syngeneic host mice.

82 apy in vitro and in vivo (in immunocompetent syngeneic hosts).

83 ive mammary cancer metastasis to the lung of syngeneic hosts.

84 tive phenotypic traits after transmission to syngeneic hosts.

85 trate that human induced Treg cells suppress syngeneic human ILC2s through ICOSL to control airway in

86 ation of nanotextile implants in orthotopic, syngeneic ID8-VEGF tumor-bearing C57BL/6 mice.

87 l alterations in tumor cells in vitro and in syngeneic immune-competent mouse models.

88 phatic drainage from murine B16 melanomas in syngeneic, immune-competent C57Bl/6 mice is associated w

89 ompared with an otherwise identical IgG in a syngeneic immunocompetent animal, and we identify TNFalp

90 otopic malignant gliomas were established in syngeneic immunocompetent mice and then treated with den

91 rexpression inhibited growth of HCC cells in syngeneic immunocompetent mice.

92 as antitumor agents for multiple targets in syngeneic, immunocompetent animal models.

93 Time course characterization of our syngeneic, immunocompetent mouse model of endometriosis

94 By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRgamma-chain knock

95 in-isolated microglia in treatment of murine syngeneic intracranial malignant gliomas.

96 Transplantation of 300 syngeneic islets into the peritoneal pouch of recipients

97 Diabetic mice were transplanted with syngeneic islets placed under the kidney capsule (KC) or

98 Six hundred syngeneic islets subcutaneously transplanted into the pr

99 Syngeneic kidney transplants (Brown Norway to Brown Norw

100 eradicate established pancreatic tumors in a syngeneic, Kras(G12D)-driven, PDAC mouse model.

101 iatrogenic interference), allogeneic but not syngeneic leukocytes could induce a rapid (after 1 d) ac

102 Syngeneic (LEW-LEW) (n = 4) and allogeneic (BN-LEW) (n =

103 wth and metastases of adoptively transferred syngeneic Lewis lung carcinoma (LLC) cells are significa

104 acity in NFAT5-deficient macrophages against syngeneic Lewis lung carcinoma and ID8 ovarian carcinoma

105 ic LXR agonist TO901317 in a murine model of syngeneic Lewis Lung carcinoma.

106 Minor skin alterations in syngeneic limbs recovered quickly; however, in allogenei

107 atment synergized with anti-PD1 therapy in a syngeneic lymphoma mouse model, resulting in marked inhi

108 ast tumor cells into the mammary fat pads of syngeneic LysMcre, HIF-1alpha (fl/fl) /LysMcre, or HIF-2

109 In a syngeneic marginal mass model of intraportal transplanta

110 breast cancer and metastasis (MMTV-PyMT), a syngeneic melanoma lung colonization model (B16F10), and

111 In mice bearing syngeneic melanoma or neuroblastoma, treatment with BNP+

112 ated to significantly reduce tumor growth in syngeneic melanoma tumor models.

113 lignancy (n = 5/group), the latter through a syngeneic metastasis approach.

114 drome leads to development of B-lymphomas in syngeneic mice and humans.

115 were subcutaneously injected into flanks of syngeneic mice and tumor growth was assessed.

116 In syngeneic mice bearing two simultaneously implanted tumo

117 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromised or Treg cell

118 is could be adoptively transferred to naive, syngeneic mice by CD4(+) T cells.

119 tly, we showed that generation of tumours in syngeneic mice by cells devoid of mitochondrial (mt) DNA

120 ctal tumors and increased tumor clearance in syngeneic mice compared with immunodeficient mice.

121 Using syngeneic mice infected acutely or chronically with 6 di

122 enic and metastatic activity when grafted in syngeneic mice or zebrafish embryos.

123 r accomplishing robust anti-PDAC immunity in syngeneic mice through the induction of immunogenic cell

124 coma cells were injected into the spleens of syngeneic mice to isolate tumour sub-populations that co

125 cle or PAHSA and splenic CD4(+) T cells from syngeneic mice were co-cultured to assess antigen presen

126 lls distributed predominantly to the lung of syngeneic mice, a frequent site of breast cancer metasta

127 f mice when injected into mammary fat pad of syngeneic mice, and demonstrated synergy when combined w

128 line recapitulated mast cell recruitment in syngeneic mice, demonstrating that this cell state can d

129 e tumorigenesis and lung metastasis model in syngeneic mice, depletion of LKB1 markedly increased tum

130 In obese syngeneic mice, metformin treatment mimicked the effects

131 cells were transplanted into 3-day wounds of syngeneic mice, only CD206(+)/CD301b(+) macrophages sign

132 In syngeneic mice, shikonin and cisplatin together, but not

133 cell-mediated response in tumor-transplanted syngeneic mice.

134 tic leukemia when infused into unconditioned syngeneic mice.

135 uced lymphatic dissemination of EMT cells in syngeneic mice.

136 are directly implanted into the left lobe of syngeneic mice.

137 tch in species but, surprisingly, also for a syngeneic mismatch in sex.

138 The syngeneic model also demonstrated a tumor-suppressing ro

139 In vivo, 4i in a mouse syngeneic model demonstrated high antitumor activity whi

140 2 function in cancer progression in a murine syngeneic model of melanoma and a mouse model of translo

141 In a syngeneic model of melanoma brain metastasis, a combinat

142 total activity for (177)Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer.

143 tivity resulted in the highest efficacy in a syngeneic model of murine prostate cancer.

144 We previously showed that ID8, a widely-used syngeneic model of ovarian cancer, lacked any of the fre

145 culminating in improvement in survival in a syngeneic model of ovarian peritoneal carcinomatosis.

146 he efficacy of PD-L1 blockade treatment in a syngeneic model of PCa by blocking both the intrinsic an

147 tastatic gene signature' derived from murine syngeneic model predicts poor patient survival in the ma

148 Furthermore, the syngeneic model showed that PDGFRalpha(+) fibroblasts in

149 apparent body weight loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.

150 C57BL/6J (allogeneic model, n = 17) and C3H (syngeneic model, n = 13) mice.

151 I-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent, and more s

152 ls rendered protection against melanoma in a syngeneic model, with decreased expression of PD-L1 and

153 rcinoma growth and blocked metastasis in the syngeneic model.

154 effects of CD47 blockade were greater in the syngeneic model.

155 d (AP20187) triggered apoptosis in 2 in vivo syngeneic models of bone tumor growth in which apoptosis

156 g in mice enhances antitumor immunity in two syngeneic models of cancer.

157 In two murine syngeneic models of TNBC, we confirmed excellent tumor t

158 n mouse triple-negative breast cancer (TNBC) syngeneic models with a TGI (tumor growth inhibition) of

159 antitumor efficacy of immunomodulator Abs in syngeneic models.

160 suppresses tumor growth in nine xenograft or syngeneic models.

161 h receptors synergizes with RT in control of syngeneic mouse breast tumor.

162 Here, we generate distinct imageable syngeneic mouse GBM-tumor models and utilize RNA-sequenc

163 d in synergistic activity in two independent syngeneic mouse glioma models by promoting migration of

164 ortalized normal human astrocytes (NHAs) and syngeneic mouse glioma models, the introduction of mutan

165 Syngeneic mouse islets (150) were transplanted either un

166 sing genetic and pharmacologic approaches on syngeneic mouse lung adenocarcinoma and human lung adeno

167 iability probe to immune cells isolated from syngeneic mouse MB49 bladder tumors, spleens, and tumor-

168 icle-encapsulated paclitaxel in subcutaneous syngeneic mouse melanoma and orthotopic xenograft lung c

169 In in vivo studies using a syngeneic mouse model bearing orthotopically injected 4T

170 or BMS-777607 cooperates with anti-PD-1 in a syngeneic mouse model for triple-negative breast cancer

171 On the syngeneic mouse model of breast cancer, the iron-crossli

172 In a syngeneic mouse model of endometriosis, IL-33 injections

173 -FAK mechanosignaling and Akt signaling in a syngeneic mouse model of metastasis.

174 2 displayed potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolonged

175 lone or in combination in an immunocompetent syngeneic mouse model of ovarian cancer.

176 CXCR2 deletion in a PDAC syngeneic mouse model produced increased fibrosis reveal

177 An orthotopic syngeneic mouse model resulted in tumours with 2.3-fold

178 inhibited tumor growth in an immunocompetent syngeneic mouse model that better recapitulates the phen

179 n this study, we used an estrogen responsive syngeneic mouse model to interrogate how a COL1A1-enrich

180 high similarity in their efficacies, using a syngeneic mouse model.

181 osis using patient samples, cell lines and a syngeneic mouse model.

182 copal effects on both 4T1 and TUBO bilateral syngeneic mouse models further demonstrate that ZnP@pyro

183 Using xenografts of human AML as well as syngeneic mouse models of leukaemia, we show that ligand

184 Lys-Mix) in both Py230 and Py8119 orthotopic syngeneic mouse models of TNBC.

185 otopically xenografted, immunodeficient, and syngeneic mouse models with genetically color-coded macr

186 Here we characterize a panel of syngeneic mouse models, representing a variety of molecu

187 In orthotopic and syngeneic mouse models, silencing or inactivating IRIS i

188 Finally, using syngeneic mouse models, we demonstrate that oncogenic Kr

189 eriments and mouse transcriptome analyses in syngeneic mouse models, we provide evidence that tumour-

190 8(+) T cells, leading to tumor inhibition in syngeneic mouse models, which was significantly attenuat

191 the lung and liver in multiple xenograft and syngeneic mouse models.

192 and therapeutic efficacy of PD-1 blockade in syngeneic mouse models.

193 anti-PD1, SG7 slows tumor growth in multiple syngeneic mouse models.

194 operties and improved transplant efficacy in syngeneic mouse PITx model.

195 ly, intravenous administration of haptenated syngeneic mouse red blood cells (sMRBC) leads to hapten-

196 s CCR2-mediated chemotaxis of monocytes in a syngeneic mouse T-cell lymphoma in skin.

197 nation with a clinical chemotherapeutic to a syngeneic mouse transplantation model of hepatic colorec

198 aded LPS-Lips in HepG2 cells in vitro and in syngeneic mouse transplants in vivo.

199 Using an orthotopic syngeneic mouse tumor model, we make the striking observ

200 survival improvements are achieved in three syngeneic mouse tumor models, including complete respons

201 In syngeneic mouse tumor models, subcutaneous and oral MSA-

202 in the tumor microenvironment using several syngeneic mouse tumor models.

203 Syngeneic MSCs given at day 0 homed to the spleen increa

204 in mice recipients of kidney allografts and syngeneic MSCs given on day 0 or on posttransplant day 2

205 e lung metastasis than with propofol in both syngeneic murine 4T1 and xenograft human MDA-MB-231 brea

206 with tumor necrosis and growth inhibition in syngeneic murine allograft tumors.

207 lines, we performed a secondary screen in a syngeneic murine AML model driven by the MLL-AF9 oncogen

208 The heterotopic syngeneic murine head and neck cancer model (mEER) cause

209 ccine-induced antitumor immune response in a syngeneic murine model of B16 melanoma.

210 CCT2 depletion in a syngeneic murine model of triple negative breast cancer

211 T cell efficacy and HLH-like toxicities in a syngeneic murine model.

212 consisting of gemcitabine and MN-siPDL1 in a syngeneic murine pancreatic cancer model resulted in a s

213 In syngeneic murine rhabdomyosarcoma models, we found that

214 opically implanted human tumor xenograft and syngeneic murine tumor models.

215 nation anti-CTLA-4 plus anti-PD-1 therapy in syngeneic murine tumors and clinical samples.

216 To establish this model, implanted syngeneic murine tumors from a mutant KRAS/p53 model wer

217 cold storage (18 hour), were transplanted to syngeneic myeloid HO-1 deficient (mHO-1 KO) or FLOX (con

218 mor growth inhibition, 67.5%) in a xenograft syngeneic non-small cell lung cancer mouse model.

219 cts were elicited by 3'3'-cGAMP injection in syngeneic or immunodeficient mice grafted with multiple

220 ses PDAC tumour cell growth in xenograft and syngeneic orthotopic animal models, and induces growth i

221 Furthermore, using a rat syngeneic orthotopic CCA model, we found that HMC inhibi

222 nations of TAM inhibitors and PD-1 mAbs in a syngeneic orthotopic E0771 murine triple-negative breast

223 Here we show using a syngeneic orthotopic implantation model of pancreatic ca

224 growth and metastasis to the lungs in a 4T1 syngeneic orthotopic mammary tumor model.

225 only significantly reduced tumor burden in a syngeneic orthotopic mouse model but also increased the

226 ysyl oxidase like-2 (anti-LOXL2) antibody in syngeneic orthotopic PDA mouse models significantly decr

227 We also used a syngeneic orthotopic PDAC mouse model to study tumor gro

228 ncreased survival in both obesity-driven and syngeneic orthotopic PDAC mouse models.

229 ify effective PDAC therapies, we leveraged a syngeneic orthotopic PDAC transplant mouse model to perf

230 Using two different syngeneic, orthotopic tumor implant models of breast can

231 ry tumors and paired lung metastases using a syngeneic p53-null mammary tumor model of basal-like bre

232 H mutations in immune response, we created a syngeneic pair mouse model for mutant IDH1 (muIDH1) and

233 efficient bioscaffold for delivery of donor syngeneic pancreatic islet cells to reverse hyperglycemi

234 e Her2/Neu-driven breast cancer model and in syngeneic pancreatic tumor (Pan02) xenografts.

235 ived microglia-like cells are conditioned by syngeneic patient-derived GBM-initiating cells.

236 ction of Mobilan into subcutaneously growing syngeneic prostate tumors in immunocompetent hosts impro

237 ntly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equi

238 Here, we used a syngeneic rat renal transplant and IRI model to evaluate

239 widely on human ovarian tumors, along with a syngeneic rat tumor model expressing human FRalpha.

240 livers, characterized, and transplanted into syngeneic recipients.

241 tion and subsequent associated graft loss in syngeneic recipients.

242 into immune-compromised or immune-competent (syngeneic) recipients.

243 Following syngeneic renal sub-capsule islet transplantation in C57

244 idney clamping) and prolonged cold ischemia (syngeneic renal transplant).

245 We also demonstrate, using a prostate cancer syngeneic RM-9 mouse model and established cell lines, t

246 Methods: C57BL/6-mice bearing syngeneic RM1-PGLS tumors were treated with (225)Ac-PSMA

247 ed of autophagosomes (DRibbles) derived from syngeneic sarcomas could induce cross-reactive T-cell re

248 In two xenograft and two syngeneic solid tumor mouse models, p40-Td CAR T cells s

249 In vivo studies using syngeneic SR-B1 WT (SR-B1(+/+)) and SR-B1 KO (SR-B1(-/-)

250 microenvironment role of RAGE, we performed syngeneic studies with orthotopically injected breast ca

251 he tumor and splenic microenvironment of two syngeneic subcutaneous (NXS2 and 9464D), and a spontaneo

252 Here, we utilized a syngeneic subcutaneous murine model of B16F10 melanoma t

253 In a syngeneic tissue recombination model of PCa and associat

254 essive myeloid-derived suppressor cells in a syngeneic TNBC mouse model.

255 nd spontaneous lung metastasis in orthotopic syngeneic TNBC mouse models.

256 Using a syngeneic TP53-null mouse model of breast cancer, we ide

257 cteristics of xenograft, chemically induced, syngeneic, transgenic, and humanized models are discusse

258 We then used a syngeneic transplant model by monitoring tumor growth fr

259 nsformation of gammadelta T-cells in in vivo syngeneic transplant models, comparable to STAT5B(N642H)

260 duced more VEC proliferation than those from syngeneic transplant recipients (P = 0.03).

261 enic changes appeared due to conditioning or syngeneic transplantation.

262 ate tumorigenic from nontumorigenic cells in syngeneic transplants.

263 Here, using a syngeneic triple negative breast cancer murine model we

264 in vitro, mirn23a (-/-) mice inoculated with syngeneic tumor cells had worse outcomes compared with w

265 essing vector and subsequent implantation of syngeneic tumor cells showed >80% GFP marking in tumor-i

266 ter vaccination with genome edited CD47(-/-) syngeneic tumor cells.

267 Further, syngeneic tumor experiments revealed that the absence of

268 pression within T cells is required to limit syngeneic tumor growth and promote IFNgamma production b

269 ulating immune cell polarization, we assayed syngeneic tumor growth in wild-type and mirn23a (-/-) mi

270 r-infiltrating CD8 expression in preclinical syngeneic tumor immunotherapy models including antigen-s

271 astasis and leads to long-term survival in a syngeneic tumor model in mice.

272 PHD3 overexpression in a syngeneic tumor model resulted in fewer liver metastases

273 ement membrane, whereas its attenuation in a syngeneic tumor model resulted in reduced metastatic col

274 s significantly controlled tumor growth in a syngeneic tumor model without evident toxicity.

275 trobacter rodentium and of tumor growth in a syngeneic tumor model.

276 demonstrate that, in three different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the

277 tumor microenvironment, we imaged a panel of syngeneic tumor models (MC38, CT26, LLC, A9F1, 4T1, and

278 ne cells to eliminate large tumor burdens in syngeneic tumor models and a genetically engineered mous

279 sed metastatic dissemination in xenograft or syngeneic tumor models in vivo.

280 and inflammatory analysis of four additional syngeneic tumor models revealed that tumors can induce f

281 any of the effects of anti-mouse GITR mAb in syngeneic tumor models, decreasing both Treg numbers and

282 d significant antitumor activity in multiple syngeneic tumor models.

283 o tumor growth inhibition in MC38 and PANC02 syngeneic tumor models.

284 immunocompetent BALB/c mice bearing the same syngeneic tumor.

285 e identify immunologically-inert and -active syngeneic-tumor types and show that inert tumors have an

286 The peptides were injected into rats with syngeneic tumors and mice with orthotopic or xenograft t

287 tumor organoids, chemoresistant xenografts, syngeneic tumors and PDX models.

288 The results showed: (1) Hepa1-6 syngeneic tumors expressed HCC-related cytokines, (2) UT

289 C57BL6/KaLwRij mice bearing murine 5TGM1-GFP syngeneic tumors generated after intravenous injection v

290 Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tum

291 ring peritoneal MKN-45P xenografts and CT-26 syngeneic tumors with IP linTT1-D(KLAKLAK)2-NWs resulted

292 within T cells during the immune response to syngeneic tumors.

293 decrease in fibrosis at PanIN lesions and in syngeneic tumors; this was due to generation of an infla

294 munotargeting of xCT in mice challenged with syngeneic tumorsphere-derived cells delayed established

295 of metastasis by TriplatinNC in the TNBC 4T1 syngeneic tumour model.

296 onstrate the method on two case studies with syngeneic tumour models which are challenging due to hig

297 efficacy of immune checkpoint inhibitors in syngeneic tumour models.

298 plantation (major histocompatibility complex syngeneic) was modeled by transplanting hearts from A-Tg

299 The stroke phenotype can be transferred to syngeneic wild-type mice via Tgfbr2(Myeko) bone marrow t

300 lls are directly implanted into the lungs of syngeneic WT mice or mice globally deficient in 5-LO (5-